Home > News > Altair Nanotechnologies Announces New Preclinical Testing
February 5th, 2004
Altair Nanotechnologies Announces New Preclinical Testing
Altair Nanotechnologies, Inc., a developer and manufacturer of innovative nanomaterial products, announced that it is planning to conduct new preclinical testing of its drug candidate, RenaZorb. The test will use an animal model directly comparing RenaZorb with existing and proposed drugs for phosphate control in patients with End Stage Renal Disease undergoing dialysis. The testing is expected to be initiated within 30 to 45 days. The company also announced that it plans to file an IND application with the U.S. Food and Drug Administration.
RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014
Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014
Journal Nanotechnology Progress International (JONPI), 2014, Volume 5, Issue 1, pp 1-24 October 22nd, 2014
TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014